"Rising Biosciences, Inc. Develops Groundbreaking Oral THC/CBD Delivery Capsule Cannophen™; Nears Completion on MMJ Laboratory in Ohio"
Press Release | 01/18/2018
SANDUSKY, Ohio, Jan. 18, 2018 (GLOBE NEWSWIRE) -- (via OTC PR WIRE) -- Rising India, Inc.’s (OTC:RSII) -- Rising Biosciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that its laboratory in Ohio is close to completion in line with the State of Ohio issuing MMJ licenses.
“Now that Ohio is beginning to issue licenses, we plan on being fully operational in our medical marijuana laboratory, which will focus on research, development, licensing and manufacturing of innovative products in the Cannabis space dedicated to serving patients with the highest standards,” states COO Arthur Hall.
“We are also thrilled to announce that included in a line of medical cannabis products, the company is debuting Cannophen™, a revolutionary product we’ve been developing for some time now. Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific tirpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures. This allows patients to take their medicine by swallowing a flavorless capsule, just like any other oral medication. We are also pleased to announce a new MMJ version of the TSW pain cream containing Cannabidiol (CBD).”
Hall adds, “There has never been any proper way to dose with the above said methods. We have developed Cannophen™ using the strictest quality and control standards and methods set forth in the pharmacy compounding industry using experienced chemists and veteran pharmacists.”
As well, Rising Biosciences is nearing completion on its FDA testing of the TSW (This Sh** Works) pain cream products.
“We’ve also had stellar feedback from those that received trial samples of the Clinical Strength Scar Peptide Serum and we now move into the next phase of production,” concludes Hall.
“Rising Biosciences Inc. along with PAO Group Inc. helping reduce the grip of opiods on America through the responsible use of cannabis”
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO: For Investor Inquiries: IR@risingbiosciences.com
Market Data 
Markets 
AI
